SEC Form 4 · accession 0001209191-16-146390
ALDER BIOPHARMACEUTICALS INC · ALDR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark James Litton
Officer — Chief Business Officer
Period of report
Oct 17, 2016
Accepted (ET)
Oct 19, 2016 · 5:51 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001423824
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Oct 17, 2016 | S | 2,000 | $27.4964 | D | 26,000 | I | Held in trust for the benefit of Reporting Person's minor child |
| Common StockF1,F3 | Oct 17, 2016 | S | 2,000 | $27.5025 | D | 26,000 | I | Held in trust for the benefit of Reporting Person's minor child |
| Common StockF1,F4 | Oct 17, 2016 | S | 2,000 | $27.50 | D | 26,000 | I | Held in trust for the benefit of Reporting Person's minor child |
| Common Stock | holding | — | — | — | 99,567 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to Rule 10b5-1 trading plans adopted by three irrevocable trusts administered by an independent trustee for the benefit of Reporting Person's minor children. The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.25 to $27.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 2 to this Form 4.
- F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.25 to $27.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 3 to this Form 4.
- F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.25 to $27.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 4 to this Form 4.